We are live on ! Find out more
GLMD icon

Galmed Pharmaceuticals
GLMD

20 hedge funds and large institutions have $19.3M invested in Galmed Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 20 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
20
Holders Change
+20
Holders Change %
–
% of All Funds
0.58%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
20
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DCM
DAFNA Capital Management
California
+$2.63M
2
PWAM
Park West Asset Management
California
+$2.6M
3
SFM
Sphera Funds Management
Israel
+$2.21M
4
6CM
683 Capital Management
New York
+$2.07M
5
VAM
Visium Asset Management
New York
+$2.01M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
DCM
1
DAFNA Capital Management
California
$2.32M +$2.63M +1,123 New
PWAM
2
Park West Asset Management
California
$2.29M +$2.6M +1,111 New
SFM
3
Sphera Funds Management
Israel
$1.95M +$2.21M +944 New
6CM
4
683 Capital Management
New York
$1.82M +$2.07M +882 New
VAM
5
Visium Asset Management
New York
$1.78M +$2.01M +860 New
Lord, Abbett & Co
6
Lord, Abbett & Co
New Jersey
$1.65M +$1.87M +798 New
HCMT
7
Highland Capital Management (Texas)
Texas
$1.46M +$1.65M +705 New
GPCM
8
Granite Point Capital Management
Massachusetts
$1.32M +$1.5M +639 New
PA
9
Perceptive Advisors
New York
$860K +$977K +417 New
HM
10
HealthCor Management
New York
$814K +$923K +394 New
KCM
11
Knoll Capital Management
Florida
$746K +$846K +361 New
GF
12
Gerry Farber
New York
$596K +$677K +289 New
HVC
13
Healthcare Value Capital
New Jersey
$574K +$651K +278 New
SM
14
Sabby Management
Florida
$360K +$408K +174 New
SKK
15
Shepherd Kaplan Krochuk
Massachusetts
$297K +$337K +144 New
Deutsche Bank
16
Deutsche Bank
Germany
$229K +$260K +111 New
SCM
17
Sterling Capital Management
North Carolina
$125K +$143K +61 New
Morgan Stanley
18
Morgan Stanley
New York
$38K +$42.2K +18 New
U
19
UBS
Switzerland
$23K +$25.8K +11 New
TRCT
20
Tower Research Capital (TRC)
New York
$15K +$16.4K +7 New

GLMD Hedge Fund Activity: Q1 2014 in Review

20 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q1 2014, worth a combined $19.3M.

Buyers outnumbered sellers: 20 funds opened new GLMD positions and 0 closed out — a net gain of 20 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was DAFNA Capital Management, opening a new position worth an estimated $2.63M.

  • 20 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q1 2014, up from 0 in Q4 2013.
  • Funds reported $19.3M of Galmed Pharmaceuticals stock for Q1 2014.
  • 20 funds opened new Galmed Pharmaceuticals positions in Q1 2014 and 0 closed out, a net change of +20 holders.
  • The largest Galmed Pharmaceuticals buyer in Q1 2014 was DAFNA Capital Management, an estimated $2.63M added.

Based on aggregated 13F filings for Q1 2014.